Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs Novartis AG — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.52, while Novartis AG trades at $150.44 (market cap $288.65B). The key difference: Novartis AG pays a 3.15% dividend while State Street SPDR Bloomberg 1-3 Month T-Bill ETF pays none, and Novartis AG is trading nearer its 52-week high, State Street SPDR Bloomberg 1-3 Month T-Bill ETF nearer its low. Which is the better fit depends on your goals.
| BIL | NVS | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $91.77 | $168.62 |
52-Week Low | $91.27 | $113.50 |
Market Cap | — | $288.65B |
Enterprise Value | — | $328.67B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
